Dr. Paul Sax highlights a phase II study that yielded “pretty spectacular results” for treating hepatitis C in his
HIV and ID Observations blog.
According to the results of a recent study, an interferon-free regimen — a fixed-dose combination of sofosbuvir and ledipasvir — has the potential to cure most patients with genotype-1 HCV infection. Although we should avoid overstating the importance of this particular treatment approach, says Dr. Paul Sax in HIV and ID Observations, there is reason to be “ecstatic” about these findings.